SCHEMBL15218331

SCHEMBL15218331

CN(CCO)c1ccc(/C=C/C(=O)c2ccccc2)cc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.61
KMT2A Q03164 6/20 0.61
RAB9A P51151 4/20 0.61
CYP1B1 Q16678 3/20 0.61
NPC1 O15118 3/20 0.61
CASP3 P42574 1/20 0.61
SMN1; SMN2 Q16637 1/20 0.61
SENP8 Q96LD8 1/20 0.61
SENP7 Q9BQF6 1/20 0.61
SENP6 Q9GZR1 1/20 0.61
CYP3A4 P08684 3/20 0.57
ALDH1A1 P00352 2/20 0.57
HPGD P15428 1/20 0.57
BCHE P06276 3/20 0.57
MAOB P27338 2/20 0.57
ACHE P22303 2/20 0.57
LMNA P02545 2/20 0.57
PLIN1 O60240 1/20 0.57
TNFRSF1A P19438 1/20 0.57
RECQL P46063 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25194276 1.00 MAPT (0.61) MAPTKMT2ARAB9ACYP1B1NPC1
SCHEMBL15218411 0.89 MAPT (0.56) MAPTKMT2ARAB9ACYP1B1NPC1
SCHEMBL15218396 0.88 MAPT (0.65) MAPTKMT2ARAB9ACYP1B1NPC1
SCHEMBL25194492 0.86 MAOB (0.59) MAPTKMT2ARAB9ACYP1B1NPC1
SCHEMBL25197170 0.86 MAOB (0.59) MAPTKMT2ARAB9ACYP1B1NPC1
SCHEMBL15216642 0.86 MAPT (0.56) MAPTKMT2ARAB9ACYP1B1NPC1
SCHEMBL25190663 0.86 MAPT (0.71) MAPTKMT2ARAB9ACYP1B1NPC1
SCHEMBL25195905 0.86 MAPT (0.71) MAPTKMT2ARAB9ACYP1B1NPC1
SCHEMBL25207425 0.86 MAPT (0.56) MAPTKMT2ARAB9ACYP1B1NPC1
SCHEMBL15218447 0.86 MAPT (0.55) MAPTKMT2ARAB9ACYP1B1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230190679-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2023-06-22 US disclosed
WO-2023086388-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2023-05-19 WO disclosed
US-8871976-B2 Chalcone structure fluorescence dye for embryonic stem cell probe NATIONAL UNIVERSITY OF SINGAPORE (SG) 2014-10-28 US disclosed
US-20130224790-A1 Chalcone Structure Fluorescence Dye For Embryonic Stem Cell Probe AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2013-08-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230190679-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS SERPINC1, SERPINE1, SERPINH1 MAPT 3512/4885KMT2A 3188/4885RAB9A 1327/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.